BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND CTNNB1, P35222, 1499, ENSG00000168036, CTNNB AND Prognosis
42 results:

  • 1. Wnt, glucocorticoid and cellular prion protein cooperate to drive a mesenchymal phenotype with poor prognosis in colon cancer.
    Mouillet-Richard S; Gougelet A; Passet B; Brochard C; Le Corre D; Pitasi CL; Joubel C; Sroussi M; Gallois C; Lavergne J; Castille J; Vilotte M; Daniel-Carlier N; Pilati C; de Reyniès A; Djouadi F; Colnot S; André T; Taieb J; Vilotte JL; Romagnolo B; Laurent-Puig P
    J Transl Med; 2024 Apr; 22(1):337. PubMed ID: 38589873
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Preclinical Repurposing of Sitagliptin as a Drug Candidate for colorectal cancer by Targeting
    Shih JW; Wu ATH; Mokgautsi N; Wei PL; Huang YJ
    Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203779
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Prognostic value of oxidative stress-related genes in colorectal cancer and its correlation with tumor immunity.
    Yang L; Fang C; Zhang R; Zhou S
    BMC Genomics; 2024 Jan; 25(1):8. PubMed ID: 38166604
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. A Subset of Pancreatoblastomas May Arise From an Adenomatous Precursor: An Ampullary Pancreatoblastoma and Adjacent Adenoma With a Shared Molecular Phenotype in an Adult Patient.
    Slack JC; Bründler MA; Box A; Koro K
    Pancreas; 2022 Nov-Dec 01; 51(10):1455-1460. PubMed ID: 37099791
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF
    Ruiz-Saenz A; Atreya CE; Wang C; Pan B; Dreyer CA; Brunen D; Prahallad A; Muñoz DP; Ramms DJ; Burghi V; Spassov DS; Fewings E; Hwang YC; Cowdrey C; Moelders C; Schwarzer C; Wolf DM; Hann B; VandenBerg SR; Shokat K; Moasser MM; Bernards R; Gutkind JS; van 't Veer LJ; Coppé JP
    Nat Cancer; 2023 Feb; 4(2):240-256. PubMed ID: 36759733
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract.
    Wu H; Yu Z; Liu Y; Guo L; Teng L; Guo L; Liang L; Wang J; Gao J; Li R; Yang L; Nie X; Su D; Liang Z
    Cancer Commun (Lond); 2022 Dec; 42(12):1367-1386. PubMed ID: 36264285
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Association of
    Yan H; Jiang F; Yang J
    Genet Res (Camb); 2022; 2022():5338956. PubMed ID: 36072013
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Comprehensive genetic characterization of rectal cancer in a large cohort of Japanese patients: differences according to tumor location.
    Hino H; Shiomi A; Hatakeyama K; Kagawa H; Manabe S; Yamaoka Y; Nagashima T; Ohshima K; Urakami K; Akiyama Y; Yamaguchi K
    J Gastroenterol; 2022 Jul; 57(7):476-485. PubMed ID: 35449312
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Identification of a Novel Five-Gene Signature as a Prognostic and Diagnostic Biomarker in colorectal cancers.
    Ghatak S; Mehrabi SF; Mehdawi LM; Satapathy SR; Sjölander A
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054980
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. SMAD4 is critical in suppression of BRAF-V600E serrated tumorigenesis.
    Tong K; Kothari OA; Haro KS; Panda A; Bandari MM; Carrick JN; Hur JJ; Zhang L; Chan CS; Xing J; Gatza ML; Ganesan S; Verzi MP
    Oncogene; 2021 Oct; 40(41):6034-6048. PubMed ID: 34453124
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Identification of m6A-Related Biomarkers Associated with prognosis of colorectal cancer.
    Zhang Z; Zhang X
    Med Sci Monit; 2021 Aug; 27():e932370. PubMed ID: 34373442
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. MEF2A transcriptionally upregulates the expression of ZEB2 and ctnnb1 in colorectal cancer to promote tumor progression.
    Xiao Q; Gan Y; Li Y; Fan L; Liu J; Lu P; Liu J; Chen A; Shu G; Yin G
    Oncogene; 2021 May; 40(19):3364-3377. PubMed ID: 33863999
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. A modified protein marker panel to identify four consensus molecular subtypes in colorectal cancer using immunohistochemistry.
    Li X; Larsson P; Ljuslinder I; Ling A; Löfgren-Burström A; Zingmark C; Edin S; Palmqvist R
    Pathol Res Pract; 2021 Apr; 220():153379. PubMed ID: 33721619
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Clinical application of next-generation sequencing for the management of desmoid tumors: A case report and literature review.
    Lee JM; Kim HG; Shin SY; Lee SH
    Medicine (Baltimore); 2021 Jan; 100(1):e24238. PubMed ID: 33429825
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. A novel immune classification reveals distinct immune escape mechanism and genomic alterations: implications for immunotherapy in hepatocellular carcinoma.
    Liu Z; Zhang Y; Shi C; Zhou X; Xu K; Jiao D; Sun Z; Han X
    J Transl Med; 2021 Jan; 19(1):5. PubMed ID: 33407585
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Questioning the IGF1 receptor's assigned role in CRC - a case for rehabilitation?
    Heckl SM; Pellinghaus M; Behrens HM; Krüger S; Schreiber S; Röcken C
    BMC Cancer; 2020 Jul; 20(1):704. PubMed ID: 32727431
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. CircAGFG1 drives metastasis and stemness in colorectal cancer by modulating YY1/ctnnb1.
    Zhang L; Dong X; Yan B; Yu W; Shan L
    Cell Death Dis; 2020 Jul; 11(7):542. PubMed ID: 32681092
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. KRAS Mutation-Responsive miR-139-5p inhibits colorectal cancer Progression and is repressed by Wnt Signaling.
    Du F; Cao T; Xie H; Li T; Sun L; Liu H; Guo H; Wang X; Liu Q; Kim T; Franklin JL; Graves-Deal R; Han W; Tian Z; Ge M; Nie Y; Fan D; Coffey RJ; Lu Y; Zhao X
    Theranostics; 2020; 10(16):7335-7350. PubMed ID: 32641995
    [No Abstract]    [Full Text] [Related]  

  • 19. Long non-coding RNA MINCR aggravates colon cancer via regulating miR-708-5p-mediated Wnt/β-catenin pathway.
    Yu Y; Chang Z; Han C; Zhuang L; Zhou C; Qi X; Peng Z
    Biomed Pharmacother; 2020 Sep; 129():110292. PubMed ID: 32535381
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Alterations in signaling pathways that accompany spontaneous transition to malignancy in a mouse model of BRAF mutant microsatellite stable colorectal cancer.
    Kane AM; Fennell LJ; Liu C; Borowsky J; McKeone DM; Bond CE; Kazakoff S; Patch AM; Koufariotis LT; Pearson J; Waddell N; Leggett BA; Whitehall VLJ
    Neoplasia; 2020 Feb; 22(2):120-128. PubMed ID: 31935636
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.